09:11 AM EDT, 08/26/2025 (MT Newswires) -- Health care stocks were edging higher premarket Tuesday, with the Health Care Select Sector SPDR Fund ( XLV ) up 0.3% and the iShares Biotechnology ETF (IBB) advancing by 0.5%.

Eli Lilly ( LLY ) shares were up 3% after the company said a phase 3 trial evaluating the investigational drug orforglipron in adults with obesity, or overweight, and type 2 diabetes met its primary and secondary endpoints.

Genmab ( GMAB ) stock was up more than 1% after the company said its investigational drug rinatabart sesutecan, or Rina-S, has been granted Breakthrough Therapy Designation by the US Food and Drug Administration for the treatment of adults with recurrent or progressive endometrial cancer that has advanced after prior treatment with platinum chemotherapy and a PD-(L)1 therapy.

Cybin ( CYBN ) shares were up more than 1% after the company said it has received approval in Australia to conduct the second pivotal study in its phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog for the adjunctive treatment of major depressive disorder.